Galera Therapeutics Inc (GRTX)
0.1875
0.00 (0.00%)
USD |
NASDAQ |
Apr 24, 16:00
0.1875
0.00 (0.00%)
After-Hours: 17:38
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 10.20M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -93.15% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | -- |
| Price to Book Value | -- |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | -- |
Profile
| Galera Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer. The Firm's lead product candidate, avasopasem manganese, is a highly selective small molecule dismutase mimetic for severe oral mucositis (SOM) in patients with head and neck cancer (HNC), the reduction of esophagitis in patients with lung cancer, and the reduction of cisplatin-induced kidney damage in patients with cancer. The Firm's second product candidate, rucosopasem manganese, has been in development to augment the anti-cancer efficacy of stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer (NSCLC) and locally advanced pancreatic cancer (LAPC). |
| URL | https://www.galeratx.com |
| Investor Relations URL | https://investors.galeratx.com/ |
| HQ State/Province | Pennsylvania |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Small Cap/Growth |
| Next Earnings Release | May. 10, 2024 (est.) |
| Last Earnings Release | Mar. 28, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Galera Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer. The Firm's lead product candidate, avasopasem manganese, is a highly selective small molecule dismutase mimetic for severe oral mucositis (SOM) in patients with head and neck cancer (HNC), the reduction of esophagitis in patients with lung cancer, and the reduction of cisplatin-induced kidney damage in patients with cancer. The Firm's second product candidate, rucosopasem manganese, has been in development to augment the anti-cancer efficacy of stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer (NSCLC) and locally advanced pancreatic cancer (LAPC). |
| URL | https://www.galeratx.com |
| Investor Relations URL | https://investors.galeratx.com/ |
| HQ State/Province | Pennsylvania |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Small Cap/Growth |
| Next Earnings Release | May. 10, 2024 (est.) |
| Last Earnings Release | Mar. 28, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |